Mizuho initiated coverage of Dentsply Sirona (XRAY) with a Neutral rating and $21 price target Dentsply Sirona has historically benefitted from its research and development innovation, which may continue with the recent launch of Primescan 2, the analyst tells investors in a research note. However, the firm believes Dentsply is witnessing economic-related softness in both its dental consumables and equipment franchises, and points out the company also has recently voluntarily temporarily suspended its Byte clear aligner franchise.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Patterson Companies initiated with a Neutral at Mizuho
- Dentsply Sirona Inc. Class Action: Levi & Korsinsky LLP Reminds Dentsply Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 27, 2025 – XRAY
- Dentsply Sirona Appoints Interim CFO Amid Investigation
- Dentsply Sirona appoints Cueto as interim Chief Financial Officer
- Dentsply Sirona price target lowered to $24 from $36 at Barrington